Introduction
============

*Helicobacter pylori* (*H. pylori*) is a Gram-negative pathogenic bacterium that can selectively colonize the stomach epithelium for the life of the host without effective eradication. Long-term carriage of *H. pylori* significantly increases the risk of developing gastritis, duodenal ulcer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma \[[@bby018-B1]\]. Although several studies have linked *H. pylori* infection to cardiovascular diseases, neurodegenerative disorders and diabetes mellitus, the association between *H. pylori* and extragastric diseases remains a matter of debate \[[@bby018-B5]\].

Despite important progress made in the management, the global emergence of *H. pylori* antibiotic resistance raises concerns about the efficacy of antibiotic therapy and requires development of new therapeutic strategies \[[@bby018-B8]\]. Developing an effective, safe and immunogenic vaccine against *H pylori* might be a smart strategy. Research on *H. pylori* vaccine for human use has been ongoing over the past 30 years. To date, the results of all the clinical vaccine trials are disappointing, except for a recent study of a three-dose oral recombinant *H pylori* vaccine in children \[[@bby018-B9], [@bby018-B10]\]. However, there is still a long way to go for this vaccine before being put in the market. Hence, understanding of the molecular pathogenic mechanism of *H. pylori* and its interaction with host is of crucial significance to the development of novel therapeutic strategies.

Many human diseases are the result of transcriptional misregulation \[[@bby018-B11]\]. Previous studies have shown that microRNAs (miRNAs) play regulatory roles in many physiological and pathological processes through downregulating target genes \[[@bby018-B12]\]. Various current studies showed the involvement of specific strains of bacteria in different diseases, including prostate cancer, lung cancer and colon cancer using computational approaches \[[@bby018-B13]\]. Thus, the identified signature miRNAs associated with *H. pylori* infection will provide novel insights into its carcinogenesis and host mechanisms that are involved in bacterial elimination. Public repository for high-throughput gene expression data, such as the Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo>) project, provides us diverse molecular data and clinical information of many diseases \[[@bby018-B17]\]. However, the predictive utility of these data for *H. pylori* infection analysis has not been systematically explored. In the present study, we aimed at identifying differentially expressed miRNAs associated with *H. pylori* infection from GEO data sets and investigated the interactions between *H. pylori* and host, and the possible damage caused by *H. pylori* infection.

Materials and methods
=====================

miRNAs expression data sets
---------------------------

The miRNA expression data sets used in this study were obtained from the GEO data sets, including GSE19769, GSE32174, GSE54397 and GSE23877 \[[@bby018-B18]\]. The data sets consisted of 31 *H. pylori*-negative samples and 41 *H. pylori*-positive samples covering gastritis, duodenal ulcer, gastric cancer and MALT lymphoma caused by *H. pylori* infection. The information of GEO data sets and patients used in this study was summarized in [Table 1](#bby018-T1){ref-type="table"}.

###### 

Descriptions of the GEO data sets and patients used in this study.

  Series accession   Country       Number of controls   Number of *H. pylori* carriers   Disease associated
  ------------------ ------------- -------------------- -------------------------------- --------------------
  GSE19769           Japan         10                   9                                Gastritis
  GSE23877           Switzerland   4                    5                                MALT lymphoma
  GSE32174           Spain         9                    19                               **Duodenal ulcer**
  GSE54397           South Korea   8                    8                                Gastric cancer

Duodenal ulcer is known as peptic ulcer. Peptic ulcer disease is a break in the lining of the stomach, first part of the small intestine or occasionally the lower esophagus.

Screening for differentially expressed miRNAs
---------------------------------------------

All collected expressed data were analyzed with GEO2R. The adjust *P* values were used to reduce the false-positive rate using Benjamini and Hochberg (false discovery rate) method by default. The adjusted *P* value \< 0.05 and \|logFC\| \> 1 were set as the cutoff criterion. Hierarchical clustering of differentially expressed miRNAs was carried out and visualized using MeV v4.8.1 \[[@bby018-B22]\].

Construction of miRNA-mRNA integrated network
---------------------------------------------

Target genes for differentially expressed miRNAs were retrieved from the miRTarBase \[[@bby018-B23]\]. miRNA-mRNA interaction network was generated using Cytoscape 3.4.0 \[[@bby018-B24]\].

Protein--protein interaction networks and gene ontology enrichment analysis
---------------------------------------------------------------------------

The protein--protein interaction network was constructed using STRING 10.0 \[[@bby018-B25]\]. Confidence score ≥ 0.9 was set as the cutoff criterion. All of the networks were visualized and analyzed with Cytoscape 3.4.0. The degrees were calculated using Centiscape 2.2 \[[@bby018-B26]\]. Hub genes were identified by degree \> 40 threshold. Metascape was used for the gene ontology (GO) enrichment analysis \[[@bby018-B27]\].

Disease connectivity analysis
-----------------------------

Diseases enriched with *H. polyri* infection-associated genes were identified using the Comparative Toxicogenomic Database (Bonferroni-corrected *P* value \< 0.05) \[[@bby018-B28]\].

Results
=======

Identification of differentially expressed miRNAs associated with *H. pylori* infection
---------------------------------------------------------------------------------------

To identify aberrant miRNAs associated with *H. pylori* infection, we analyzed four public GEO data sets (GSE19769, GSE23877, GSE32174 and GSE54397). The derived data sets consisted of 31 *H. pylori*-negative samples and 41 *H. pylori*-positive samples from Asia and Europe ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Four common *H. pylori* infection-related diseases (gastritis, duodenal ulcer, gastric cancer and MALT lymphoma) were included in this study. In total, 45, 249, 8 and 54 differentially expressed miRNAs were identified from GSE19769, GSE23877, GSE32174 and GSE54397, respectively ([Figure 1A--D](#bby018-F1){ref-type="fig"}). As shown in the Venn diagram ([Figure 1E](#bby018-F1){ref-type="fig"}), we filtered out 34 differentially expressed miRNAs that at least occurred in two data sets. The expression of these 34 miRNAs in the data sets was listed in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}. miRNAs with the smallest *P* values will be the most reliable. Among these 34 miRNAs, 3 miRNAs (hsa-let-7c, hsa-miR-204 and hsa-miR-551 b) were overlapped in three data sets. These 34 miRNAs were considerate to be *H. pylori* infection related miRNAs.

![Identification of differentially expressed miRNAs associated with *H. pylori* infection. (**A-D**) Heat maps of miRNA microarray analysis. Each column contains the data from a specific gene and each row contains data from single sample. Upregulated expression levels are in red and downregulated in green. The fold-changes (log2 transformed) of miRNA expression in *H. pylori*-negative samples versus *H. pylori*-positive samples from GSE19769 (**A**; gastritis), GSE32174 (**B**; duodenal ulcer), GSE54397 (**C**; gastric cancer), GSE23877 (**D**; MALT lymphoma). In total, 45 249 8 and 54 differentially expressed miRNAs were identified from GSE19769, GSE23877, GSE32174 and GSE54397, respectively. (**E)** Venn diagram of overlap of differentially expressed miRNAs. We filtered out 34 differentially expressed miRNAs that at least occurred in two datasets. Among these 34 miRNAs, hsa-let-7c, hsa-miR-204 and hsa-miR-551 b were overlapped in three data sets.](bby018f1){#bby018-F1}

Targets prediction and miRNAs-targets interaction
-------------------------------------------------

As an miRNA exerts its biological regulatory function through all of its target genes at the posttranscriptional level, to understand the potential role of these 34 miRNAs in the pathogenesis of *H. pylori*, we obtained 765 highly reliable miRNA target genes from miRTarBase data set. These target genes are validated by at least one of strongly experimental methods (reporter assay, Western blot or quantitative real-time poymerase chain reaction). Six miRNAs (hsa-miR-551 b, hsa-miR-557, hsa-miR-571, hsa-miR-875-3p, hsa-miR-924 and hsa-miR-943) have no strong experimental evidences supported. We found that miR-155 regulates the most target genes (247 genes) in the miRNA-mRNA regulatory network ([Figure 2](#bby018-F2){ref-type="fig"}). Among these target genes, 25.9% genes have 2 or more miRNA predictive binding sites, especially *BCL2* can be targeted by up to 9 of the 34 miRNAs, and 32 genes have 5 or more predictive miRNA binding sites ([Table 2](#bby018-T2){ref-type="table"}). These 765 miRNA target genes may play important roles during *H. pylori* colonization and persistent infection.

###### 

Target genes with five or more predictive miRNA-binding sites

  Target genes   miRNA counts   miRNA
  -------------- -------------- ----------------------------------------------------------------------------------------------------------------------
  *BCL2*         9              hsa-let-7a, hsa-miR-33b, hsa-miR-136, hsa-miR-200b, hsa-miR-200c, hsa-miR-204, hsa-miR-206, hsa-miR-375, hsa-miR-429
  *MYC*          7              hsa-let-7a, hsa-let-7c, hsa-let-7f, hsa-miR-33b, hsa-miR-106b, hsa-miR-155, hsa-miR-429
  *ZEB2*         7              hsa-miR-141, hsa-miR-154, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, hsa-miR-203, hsa-miR-429
  *MALAT1*       7              hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, hsa-miR-204, hsa-miR-375, hsa-miR-429
  *HMGA2*        6              hsa-let-7a, hsa-let-7c, hsa-miR-33b, hsa-miR-154, hsa-miR-196a, hsa-miR-204,
  *CCND2*        6              hsa-let-7a, hsa-miR-106b, hsa-miR-154, hsa-miR-155, hsa-miR-203, hsa-miR-206,
  *CDKN1A*       6              hsa-let-7a, hsa-let-7f, hsa-miR-106b, hsa-miR-196a, hsa-miR-203, hsa-miR-519e
  *VEGFA*        6              hsa-miR-106b, hsa-miR-200b, hsa-miR-200c, hsa-miR-203, hsa-miR-206, hsa-miR-429
  *PTEN*         6              hsa-miR-106b, hsa-miR-141, hsa-miR-155, hsa-miR-200a, hsa-miR-200c, hsa-miR-429
  *ZEB1*         6              hsa-miR-33b, hsa-miR-141, hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, hsa-miR-429

![Regulatory network between miRNA and their target genes. Target genes for differentially expressed miRNAs were retrieved from the miRTarBase. These target genes were validated by at least one of strongly experimental methods (reporter assay, Western blot or quantitative real-time polymerase chain reaction). We also linked these differentially expressed miRNAs to the diseases that were diagnosed in the patients. This network was generated using Cytoscape 3.4.0 and consisted of 4 *H. pylori* infection-related diseases, 28 miRNAs and 765 genes. Rectangle (yellow) represents diseases, ellipses (green) represents genes and triangle represents miRNAs.](bby018f2){#bby018-F2}

Functional enrichment analysis of miRNA target genes
----------------------------------------------------

Next, we performed GO and KEGG pathway enrichment analysis using Metascape for 765 *H. pylori* infection-associated genes, and the most significantly enriched gene sets were pathways in cancer (hsa05200) and negative regulation of transcription from RNA polymerase II promoter (GO: 0000122) ([Figure 3A](#bby018-F3){ref-type="fig"}). This analysis also revealed that *H. pylori* infection was largely related to cardiovascular system development (GO: 0072358), gland development (GO: 0048732), hematopoietic or lymphoid organ development (GO: 0048534), proteoglycans in cancer (hsa05205) and heart development (GO: 0007507). Interestingly, all these biological processes identified with a significant *P* value were closely interrelated except for response to oxygen levels (GO: 0070482) ([Figure 3B](#bby018-F3){ref-type="fig"}). These results indicate that *H. pylori* infection could negatively regulate the synthesis of mRNA, many of which may influence the development of cancer and other human diseases.

![Functional enrichment analysis of miRNA target genes. (**A**) Top 20 clusters from Metascape pathway enrichment analysis of the 765 *H. pylori* infection-associated genes. Length of bars represent log~10~ (P value) based on the best-scoring term within each cluster. (**B**) Relationships among these top 20 clusters enrichment terms displayed as a network analyzed by Metascape. Nodes of the same color belonged to the same cluster. Terms with a similarity score \> 0.3 were linked by an edge. The network was visualized with Cytoscape with 'force-directed' layout and with edge bundled for clarity.](bby018f3){#bby018-F3}

Disease connectivity analysis
-----------------------------

To reduce interference of unrelated genes and the complexity of the list of *H. pylori* infection associated genes, 28 genes were identified as hub genes ([Figure 4A](#bby018-F4){ref-type="fig"} and [Table 3](#bby018-T3){ref-type="table"}). We found that these hub genes could interact with each other and are target of 21 of 28 *H. pylori* infection associated miRNAs ([Figure 4B](#bby018-F4){ref-type="fig"}). Disease connectivity analysis of these 28 hub genes showed *H. pylori* infection significantly associated with cancer, digestive system disease, urogenital disease, cardiovascular disease, respiratory tract disease and immune system disease ([Figure 4C](#bby018-F4){ref-type="fig"} and [Table 4](#bby018-T4){ref-type="table"}). *H. pylori* infection is also strongly associated with blood disease, lymphatic disease, endocrine system disease, nervous system disease and skin disease ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Taken together, these results demonstrate that *H. pylori* colonizes the gastric epithelium, but beyond gastric diseases.

###### 

The degree, betweenness and closeness of 28 hub genes analyzed with Centiscape 2.2

  Name       Degree   Betweenness   Closeness
  ---------- -------- ------------- ------------
  *PIK3CA*   74       0.03170252    0.46114519
  *CTNNB1*   72       0.08612305    0.46590909
  *JUN*      72       0.06560389    0.46784232
  *MYC*      71       0.10257151    0.47978723
  *AKT1*     66       0.06789642    0.47423764
  *PIK3R1*   65       0.0222343     0.45145145
  *RAC1*     64       0.05136969    0.4500998
  *MAPK3*    61       0.04631864    0.45694022
  *SRC*      58       0.02860764    0.44302554
  *MAPK14*   57       0.04698078    0.46399177
  *RHOA*     56       0.03652856    0.44521224
  *EGFR*     53       0.04216526    0.44042969
  *HRAS*     53       0.02578029    0.42993327
  *GRB2*     51       0.01993267    0.4187558
  *FOS*      49       0.0236865     0.44831014
  *CDC42*    49       0.03134559    0.41759259
  *SMAD4*    49       0.02615774    0.42110177
  *CCND1*    48       0.02644287    0.44565217
  *SHC1*     47       0.01052397    0.41605166
  *FYN*      47       0.01772007    0.42427093
  *JAK2*     46       0.01814914    0.40851449
  *JAK1*     45       0.0171368     0.42467043
  *SMAD3*    45       0.02195681    0.42627599
  *IL2*      44       0.01386536    0.42993327
  *E2F1*     43       0.01451441    0.40231936
  *NFKB1*    42       0.03770201    0.43574879
  *CDKN1A*   42       0.01303738    0.4254717
  *NRAS*     42       0.00935047    0.40412186

###### 

Top 25 enriched diseases of 28 hub genes analyzed with the Comparative Toxicogenomics Database

  Disease name                                                Disease categories                 *P* value   Corrected *P* value   Annotated genes quantity   Annotated genes                                                                                                                            Genome frequency
  ----------------------------------------------------------- ---------------------------------- ----------- --------------------- -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ --------------------------
  Digestive system neoplasms                                  Cancer digestive system disease    4.16E-30    2.55E-27              22                         *AKT1 CCND1 CDKN1A CTNNB1 E2F1 EGFR FOS FYN HRAS IL2 JAK2 JUN MAPK14 MAPK3 MYC NFKB1 NRAS PIK3CA RAC1 RHOA SMAD4 SRC*                      1118/42 703 genes: 2.62%
  Neoplasms by histologic type                                Cancer                             6.77E-30    4.16E-27              24                         *AKT1 CCND1 CDC42 CDKN1A CTNNB1 E2F1 EGFR FOS FYN HRAS IL2 JAK2 JUN MAPK14 MAPK3 MYC NFKB1 NRAS PIK3CA PIK3R1 RAC1 RHOA SMAD3 SMAD4*       1742/42 703 genes: 4.08%
  Neoplasms by site                                           Cancer                             6.19E-29    3.80E-26              25                         *AKT1 CCND1 CDC42 CDKN1A CTNNB1 E2F1 EGFR FOS FYN HRAS IL2 JAK2 JUN MAPK14 MAPK3 MYC NFKB1 NRAS PIK3CA PIK3R1 RAC1 RHOA SMAD3 SMAD4 SRC*   2325/42 703 genes: 5.44%
  Cardiovascular diseases                                     Cardiovascular disease             6.85E-27    4.21E-24              21                         *AKT1 CCND1 CDKN1A CTNNB1EGFR FOS HRAS IL2 JAK2 JUN MAPK14 MAPK3 MYC NFKB1 NRAS PIK3CA RAC1 SHC1 SMAD3 SMAD4 SRC*                          1267/42 703 genes: 2.97%
  Pathologic processes                                        Pathology (process)                3.98E-26    2.44E-23              21                         *AKT1 CCND1 CDC42 CDKN1A CTNNB1 EGFR FOS HRAS IL2 JAK2 JUN MAPK3 MYC NFKB1 NRAS PIK3CA PIK3R1 RAC1 RHOA SMAD4 SRC*                         1378/42 703 genes: 3.23%
  Pathological conditions, signs and symptoms                                                    5.74E-26    3.52E-23              24                         *AKT1 CCND1 CDC42 CDKN1A CTNNB1 EGFR FOS FYN HRAS IL2 JAK2 JUN MAPK3 MYC*                                                                  2542/42 703 genes: 5.95%
  *NFKB1 NRAS PIK3CA PIK3R1 RAC1 RHOA SHC1 SMAD3 SMAD4 SRC*                                                                                                                                                                                                                                              
  Carcinoma                                                   Cancer                             6.12E-26    3.76E-23              19                         *AKT1 CCND1 CDC42 CDKN1A CTNNB1 E2F1 EGFR FOS HRAS JUN MAPK3 MYC NFKB1 NRAS PIK3CA PIK3R1 RAC1 RHOA SMAD4*                                 895/42 703 genes: 2.10%
  Neoplasms, glandular and epithelial                         Cancer                             7.82E-26    4.80E-23              20                         *AKT1 CCND1 CDC42 CDKN1A CTNNB1 E2F1 EGFR FOS HRAS IL2 JUN MAPK3 MYC NFKB1 NRAS PIK3CA PIK3R1 RAC1 RHOA SMAD4*                             1144/42 703 genes: 2.68%
  Neoplasms                                                   Cancer                             1.11E-25    6.85E-23              25                         *AKT1 CCND1 CDC42 CDKN1A CTNNB1 E2F1 EGFR FOS FYN HRAS IL2 JAK2 JUN MAPK14 MAPK3 MYC NFKB1 NRAS PIK3CA PIK3R1 RAC1 RHOA SMAD3 SMAD4 SRC*   3141/42 703 genes: 7.36%
  Digestive system diseases                                   Digestive system disease           1.42E-24    8.72E-22              23                         *AKT1 CCND1 CDKN1A CTNNB1 E2F1 EGFR FOS FYN HRAS IL2 JAK2 JUN MAPK14 MAPK3 MYC NFKB1 NRAS PIK3CA RAC1 RHOA SMAD3 SMAD4 SRC*                2419/42 703 genes: 5.66%
  Gastrointestinal diseases                                   Digestive system disease           2.73E-23    1.67E-20              18                         *AKT1 CCND1 CDKN1A CTNNB1 EGFR FYN HRAS JAK2 JUN MAPK3 MYC NFKB1 NRAS PIK3CA RHOA SMAD3 SMAD4 SRC*                                         978/42703 genes: 2.29%
  Gastrointestinal neoplasms                                  Cancer digestive system disease    1.68E-21    1.03E-18              16                         *AKT1 CCND1 CDKN1A CTNNB1 EGFR FYN HRAS JUN MAPK3 MYC NFKB1 NRAS PIK3CA RHOA SMAD4 SRC*                                                    748/42 703 genes: 1.75%
  Hemic and lymphatic diseases                                                                   1.68E-21    1.03E-18              16                         *AKT1 CCND1 CDC42 CTNNB1 FYN HRAS IL2 JAK2 MAPK14 MYC NRAS PIK3CA PIK3R1 RHOA SMAD4 SRC*                                                   748/42 703 genes: 1.75%
  Liver neoplasms                                             Cancer digestive system disease    2.04E-21    1.25E-18              14                         *CCND1 CTNNB1 E2F1 EGFR FOS HRAS IL2 JAK2 JUN MAPK14 MAPK3 MYC PIK3CA RAC1*                                                                417/42 703 genes: 0.98%
  Neoplastic processes                                        Cancer pathology (process)         2.58E-21    1.59E-18              14                         *CCND1 CTNNB1 EGFR FOS HRAS IL2 JUN MAPK3 MYC NFKB1 PIK3CA RAC1 RHOA SRC*                                                                  424/42 703 genes: 0.99%
  Liver diseases                                              Digestive system disease           4.74E-21    2.91E-18              19                         *CCND1 CDKN1A CTNNB1 E2F1 EGFR FOS FYN HRAS IL2 JAK2 JUN MAPK14 MAPK3 MYC NFKB1 PIK3CA RAC1 SMAD3 SMAD4*                                   1624/42 703 genes: 3.80%
  Intestinal diseases                                         Digestive system disease           1.42E-19    8.70E-17              14                         *AKT1 CCND1 CDKN1A CTNNB1 EGFR JAK2 JUN MYC NFKB1 NRAS PIK3CA SMAD3 SMAD4 SRC*                                                             564/42 703 genes: 1.32%
  Female urogenital diseases                                  Urogenital disease (female)        2.03E-19    1.25E-16              17                         *AKT1 CCND1 CDKN1A CTNNB1 EGFR FOS HRAS IL2 JAK2 MAPK3 MYC NFKB1 PIK3CA PIK3R1 RHOA SMAD3 SRC*                                             1289/42 703 genes: 3.02%
  Colonic diseases                                            Digestive system disease           4.14E-19    2.54E-16              13                         *AKT1 CCND1 CDKN1A CTNNB1 EGFR JAK2 JUN MYC NFKB1 NRAS PIK3CA SMAD4 SRC*                                                                   441/42 703 genes: 1.03%
  Lung neoplasms                                              Cancer respiratory tract disease   5.55E-19    3.41E-16              13                         *AKT1 CCND1 CDKN1A CTNNB1 EGFR FOS HRAS IL2 JUN MAPK14 MAPK3 MYC PIK3CA*                                                                   451/42 703 genes: 1.06%
  Respiratory tract neoplasms                                 Cancer respiratory tract disease   6.41E-19    3.93E-16              13                         *AKT1 CCND1 CDKN1A CTNNB1 EGFR FOS HRAS IL2 JUN MAPK14 MAPK3 MYC PIK3CA*                                                                   456/42 703 genes: 1.07%
  Thoracic neoplasms                                          Cancer                             6.59E-19    4.05E-16              13                         *AKT1 CCND1 CDKN1A CTNNB1 EGFR FOS HRAS IL2 JUN MAPK14 MAPK3 MYC PIK3CA*                                                                   457/42 703 genes: 1.07%
  Female urogenital diseases and pregnancy complications                                         1.16E-18    7.10E-16              17                         *AKT1 CCND1 CDKN1A CTNNB1 EGFR FOS HRAS IL2 JAK2 MAPK3 MYC NFKB1 PIK3CA PIK3R1 RHOA SMAD3 SRC*                                             1430/42 703 genes: 3.35%
  Immune system diseases                                      Immune system disease              1.73E-18    1.06E-15              16                         *AKT1 CCND1 CDC42 CDKN1A CTNNB1 FOS FYN IL2 JUN MYC NFKB1 NRAS PIK3CA PIK3R1 RHOA SMAD3*                                                   1158/42 703 genes: 2.71%
  Colorectal neoplasms                                        Cancer digestive system disease    3.89E-18    2.39E-15              12                         *AKT1 CCND1 CDKN1A CTNNB1 EGFR JUN MYC NFKB1 NRAS PIK3CA SMAD4 SRC*                                                                        369/42 703 genes: 0.86%

![Hub genes and disease connectivity analysis. (**A**) The protein--protein interaction network of 765 genes was generated using STRING (confidence score ≥ 0.9) and visualized with Cytoscape 3.4.0. The node properties, such as degree, were calculated using Centiscape 2.2. In total, 28 hub genes were identified according to degree \> 40 threshold. (**B**) STRING-generated interaction network among the 28 hub genes and miRNA-mRNA interaction predicted with miRTarBase were described in 'Materials and methods' section. Then miRNA--hub gene--disease network was visualized with Cytoscape 3.4.0. This network consists of 4 *H. pylori* infection-related diseases, 21 miRNAs and 28 genes. (**C**) Diseases or conditions enriched with *H. pylori* infection associated genes were identified using the 'set analyzer' tool of the Comparative Toxicogenomic Database with Bonferoni-corrected *P* value \< 0.05. The corrected *P* value is calculated by the hypergeometric distribution and adjusted for multiple testing using the Bonferroni method. Diseases with the smallest *P* values mean the most reliable connectivity between a disease and genes analyzed.](bby018f4){#bby018-F4}

Discussion
==========

This integrated study of 31 *H. pylori*-negative samples and 41 *H. pylori*-positive samples provides numerous novel insights into *H. pylori* infection associated diseases and delineates multiple potential opportunities for therapeutic intervention. Several of the differentially expressed miRNAs identified in this study, particularly hsa-let-7c, hsa-miR-204 and hsa-miR-551 b, are amenable in principle to diagnostic biomarkers and therapeutic targets. Previous studies demonstrated that downregulation of has-miR-204 promoted epithelial--mesenchymal transition in *H.pylori*-induced gastric cancer by targeting *SOX4* \[[@bby018-B29]\]. Decreased hsa-let-7c significantly associated with the increasing severity of the histological lesions in *H. pylori*-related carcinogenesis, but the molecular mechanisms are still largely unclear \[[@bby018-B30]\]. So far, no evidence has shown that hsa-miR-551 b was clearly associated with *H. pylori* infection and may serve as a novel *H. pylori* infection-related miRNA biomarker in clinical use.

In this study, we also constructed miRNA-target mRNA network based on mirTarbase database. The result showed that miR-155, miR-203, miR-204 and miR-200 family (miR-200a, miR-200 b, miR-200c, miR-141 and miR-429) were central miRNAs. Eleven target genes (*BCL2, MYC, ZEB2, MALAT1, HMGA2, CCND2, CDKN1A, VEGFA, PTEN* and *ZEB1*) most connected with differentially expressed miRNAs in this network. The data here suggest that these miRNAs and target genes may also exert important biological functions in the progression of *H. pylori* infection. As expected, GO enrichment analysis of miRNA target genes showed that the most significantly enriched gene sets were pathways in cancer and negative regulation of transcription from RNA polymerase II promoter. We also identified a number of previously unappreciated biological processes and pathways closely related to *H. pylori* infection, such as hematopoietic or lymphoid organ development, heart development.

A total of 28 target genes were identified as hubs that occupy central positions in protein--protein interaction network. Several hubs have shown important regulatory functions during *H. pylori* infection. For example, *H. pyloriCagA* promotes the expression of the proto-oncogenes *c-JUN* and regulates FasL-dependent T-cell apoptosis \[[@bby018-B31], [@bby018-B32]\]. *c-Myc* acts as an important mediator of macrophage activation and contributes to the mucosal inflammatory response to *H. pylori* infection by its transactivation of the ornithine decarboxylase promoter \[[@bby018-B33]\]. However, we are still largely unknown about the functional role of these hub genes identified in this study, such as *CTNNB1* and *RHOA*, providing a new direction in the future research.

Disease connectivity analysis of 28 hub genes predicted that 228 items of human diseases are related to *H. pylori* infection, including cancer, cardiovascular disease, digestive system disease, urogenital disease and immune system disease, many of which are overlapped with previous reports \[[@bby018-B34]\]. H*. pylori* infection is also significantly associated with hemic and lymphatic diseases, respiratory tract disease, endocrine system disease, nervous system disease and skin disease. The possible mechanism includes molecular mimicry, epithelial injury and chronic inflammation \[[@bby018-B38]\]. However, evidence now supports the tenet that bacterial dysbiosis plays an important role in human disease \[[@bby018-B41]\]. *H. pylori* infection not only directly injures host cells but also changes the gastric environment and mucosal barrier, initiating the inflammatory cascades and altering the microbiota \[[@bby018-B42]\]. These findings demonstrate the importance of examining *H. pylori* infection in the treatment of other extra-gastric diseases.

Conclusions
===========

Our current prediction work demonstrated a new method to predict pathogen--human disease connectivity based on miRNA-mRNA interaction network. Furthermore, this integrated network analysis revealed a profound impact of *H. pylori* infection on various human extra-gastric diseases. The curated omics data may also provide an important resource for future studies.

Key PointsComprehensive analysis of *H. pylori* infection-associated miRNAs.Integrated analysis of *H. pylori* infection-associated human extra-gastric diseases.A new method to predict pathogen--human disease connectivity based on miRNA-mRNA interaction network.
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